Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: PYD001
MIFTS: 55

Pyoderma Gangrenosum

Categories: Bone diseases, Rare diseases, Skin diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Pyoderma Gangrenosum

About this section

MalaCards integrated aliases for Pyoderma Gangrenosum:

Name: Pyoderma Gangrenosum 12 77 54 60 56 45 15 17 74

Characteristics:

Orphanet epidemiological data:

60
pyoderma gangrenosum
Prevalence: 1-9/100000 (United States),1-9/1000000 (United Kingdom),1-9/1000000 (Spain),1-9/1000000 (Worldwide); Age of onset: Adolescent,Adult,Childhood,Elderly; Age of death: normal life expectancy;

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Skin diseases Bone diseases
See all MalaCards categories (disease lists)
ICD10: 34 35
Orphanet: 60  
Rare systemic and rhumatological diseases
Rare skin diseases


External Ids:

Disease Ontology 12 DOID:8553
ICD9CM 36 686.01
MeSH 45 D017511
SNOMED-CT 69 74578003
ICD10 34 L88
MESH via Orphanet 46 D017511
ICD10 via Orphanet 35 L88
UMLS via Orphanet 75 C0085652
Orphanet 60 ORPHA48104
UMLS 74 C0085652
Sources

Summaries for Pyoderma Gangrenosum

About this section
NIH Rare Diseases : 54 Pyoderma gangrenosum is a rare, destructive inflammatory skin disease of which a painful nodule or pustule breaks down to form a progressively enlarging ulcer. Lesions may occur either in the absence of any apparent underlying disorder or in association with other diseases, such as ulcerative colitis, Crohn's disease, polyarthritis (an inflammation of several joints together), gammopathy, vasculitis, leukemia, and other conditions. Each year in the United States, pyoderma gangrenosum occurs in about 1 person per 100,000 people. Pyoderma gangrenosum belongs to a group of autoinflammatory skin diseases called neutrophilic dermatoses. Neutrophils are a type of white blood cell or leukocyte which form an early line of defense against bacterial infections. Ulcerations associated with pyoderma gangrenosum may occur after trauma or injury to the skin, a process called pathergy. Treatment involves wound care and the use of anti-inflammatory agents, including antibiotics, corticosteroids, immunosuppressants, and biologics. 

MalaCards based summary : Pyoderma Gangrenosum is related to ileocolitis and colitis. An important gene associated with Pyoderma Gangrenosum is PSTPIP1 (Proline-Serine-Threonine Phosphatase Interacting Protein 1), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Infliximab and Dermatologic Agents have been mentioned in the context of this disorder. Affiliated tissues include skin, neutrophil and myeloid, and related phenotypes are fever and arthralgia

Wikipedia : 77 Pyoderma gangrenosum is a rare, inflammatory skin disease where painful pustules or nodules become... more...

Sources

Related Diseases for Pyoderma Gangrenosum

About this section

Diseases related to Pyoderma Gangrenosum via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 382)
# Related Disease Score Top Affiliating Genes
1 ileocolitis 32.5 NOD2 TNF
2 colitis 31.5 CXCL8 NOD2 TNF
3 ulcerative colitis 31.4 CXCL8 NOD2 TNF
4 hidradenitis 31.4 NOD2 TNF
5 inflammatory bowel disease 31.1 CXCL8 NOD2 TNF
6 hidradenitis suppurativa 31.1 NOD2 TNF
7 pyoderma 31.1 CXCL8 IFNA2 ITGB2 MEFV NOD2 PSTPIP1
8 arthritis 31.0 CXCL8 NOD2 PSTPIP1 TNF
9 fasciitis 31.0 CXCL8 TNF
10 vasculitis 31.0 IFNA2 MEFV TNF
11 scleritis 30.7 ITGB2 TNF
12 sapho syndrome 30.6 CXCL8 NOD2
13 crohn's colitis 30.6 CXCL8 NOD2 TNF
14 pouchitis 30.6 CXCL8 NOD2
15 erysipelas 30.3 MEFV TNF
16 spondylarthropathy 30.3 NOD2 TNF
17 polyarteritis nodosa 30.2 IFNA2 MEFV
18 ileitis 30.2 NOD2 TNF
19 stomatitis 30.1 IFNA2 MEFV TNF
20 uveitis 30.0 IFNA2 NOD2 TNF
21 acute respiratory distress syndrome 30.0 CXCL8 TNF
22 mooren's ulcer 29.8 ITGB2 NLRP3
23 aphthous stomatitis 29.7 MEFV NLRP3 TNF
24 behcet syndrome 29.3 CXCL8 IFNA2 MEFV NOD2 PSTPIP1 TNF
25 pyogenic sterile arthritis, pyoderma gangrenosum, and acne 13.0
26 bullous pyoderma gangrenosum 12.5
27 vegetative pyoderma gangrenosum 12.5
28 classic pyoderma gangrenosum 12.5
29 pyoderma gangrenosum-acne-suppurative hidradenitis syndrome 12.5
30 pustular pyoderma gangrenosum 12.5
31 crohn's disease 11.8
32 corticosteroid-sensitive aseptic abscesses 11.4
33 polydactyly, postaxial, type a1 11.4
34 neurofibromatosis, type ii 10.7
35 leukemia 10.7
36 myelodysplastic syndrome 10.7
37 rheumatoid arthritis 10.6
38 lymphoma 10.6
39 hepatitis 10.6
40 breast reconstruction 10.5
41 myelofibrosis 10.4
42 necrotizing fasciitis 10.4
43 systemic lupus erythematosus 10.4
44 osteomyelitis 10.4
45 lupus erythematosus 10.4
46 psoriasis 10.4
47 dermatitis 10.4
48 subcorneal pustular dermatosis 10.4
49 myeloma, multiple 10.3
50 granulomatosis with polyangiitis 10.3

Graphical network of the top 20 diseases related to Pyoderma Gangrenosum:



Diseases related to Pyoderma Gangrenosum
Sources

Symptoms & Phenotypes for Pyoderma Gangrenosum

About this section

Human phenotypes related to Pyoderma Gangrenosum:

60 33 (show all 15)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 fever 60 33 hallmark (90%) Very frequent (99-80%) HP:0001945
2 arthralgia 60 33 hallmark (90%) Very frequent (99-80%) HP:0002829
3 skin ulcer 60 33 hallmark (90%) Very frequent (99-80%) HP:0200042
4 myalgia 60 33 hallmark (90%) Very frequent (99-80%) HP:0003326
5 papule 60 33 hallmark (90%) Very frequent (99-80%) HP:0200034
6 myositis 60 33 hallmark (90%) Very frequent (99-80%) HP:0100614
7 myelodysplasia 60 33 frequent (33%) Frequent (79-30%) HP:0002863
8 inflammation of the large intestine 60 33 frequent (33%) Frequent (79-30%) HP:0002037
9 increased antibody level in blood 60 33 frequent (33%) Frequent (79-30%) HP:0010702
10 rheumatoid arthritis 60 33 frequent (33%) Frequent (79-30%) HP:0001370
11 pustule 60 33 frequent (33%) Frequent (79-30%) HP:0200039
12 atrophic scars 60 33 frequent (33%) Frequent (79-30%) HP:0001075
13 myeloid leukemia 60 33 frequent (33%) Frequent (79-30%) HP:0012324
14 abnormal blistering of the skin 60 33 occasional (7.5%) Occasional (29-5%) HP:0008066
15 skin vesicle 60 33 occasional (7.5%) Occasional (29-5%) HP:0200037

MGI Mouse Phenotypes related to Pyoderma Gangrenosum:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 9.17 ITGB2 MEFV MMP10 NLRP3 NOD2 PSTPIP1
Sources

Drugs & Therapeutics for Pyoderma Gangrenosum

About this section

Drugs for Pyoderma Gangrenosum (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 40)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Infliximab Approved Phase 4,Not Applicable 170277-31-3
2 Dermatologic Agents Phase 4,Phase 2,Not Applicable
3 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Not Applicable
4 Gastrointestinal Agents Phase 4,Not Applicable
5
Minocycline Approved, Investigational Phase 3 10118-90-8 5281021
6
Adalimumab Approved Phase 2, Phase 3,Phase 3 331731-18-1 16219006
7
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
8
Azathioprine Approved Phase 3 446-86-6 2265
9
carbamide peroxide Approved Phase 3 124-43-6
10 Anti-Bacterial Agents Phase 3
11 Anti-Infective Agents Phase 3
12 Anti-Inflammatory Agents, Non-Steroidal Phase 3
13 Anti-Inflammatory Agents Phase 3,Phase 2
14 Peripheral Nervous System Agents Phase 3
15 Analgesics, Non-Narcotic Phase 3
16 Mesalamine Phase 3,Phase 2 89-57-6
17 Analgesics Phase 3
18 N-Methylaspartate Phase 3
19 Immunosuppressive Agents Phase 3,Phase 2
20 Antimetabolites Phase 3
21 Hormones Phase 3
22 glucocorticoids Phase 3
23 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3
24 Liver Extracts Phase 3
25 alanine Phase 3
26 Antimetabolites, Antineoplastic Phase 3
27 Antineoplastic Agents, Hormonal Phase 3
28 Hormone Antagonists Phase 3
29 Immunologic Factors Phase 3,Phase 2,Phase 1
30 Aspartic Acid Phase 3
31 Pharmaceutical Solutions Phase 3,Phase 2
32 Ixekizumab Approved, Investigational Phase 2 1143503-69-8
33
Tacrolimus Approved, Investigational Phase 2 104987-11-3 6473866 445643 439492
34 Antibodies Phase 2,Phase 1
35 Immunoglobulins Phase 2,Phase 1
36 Antibodies, Monoclonal Phase 2,Phase 1
37 Calcineurin Inhibitors Phase 2
38
Certolizumab pegol Approved 428863-50-7
39 Vedolizumab Approved 943609-66-3
40
Ustekinumab Approved, Investigational 815610-63-0

Interventional clinical trials:

(show all 27)
# Name Status NCT ID Phase Drugs
1 Infliximab for the Prevention of Recurrent Crohn's Disease After Surgery Completed NCT00688636 Phase 4 infliximab;placebo
2 Minocycline Therapy for Lung Scarring in Patients With Idiopathic Pulmonary Fibrosis - a Pilot Study Unknown status NCT00203697 Phase 3 minocycline
3 A Comparison of Once a Day Dose Compared to 2 Doses/Day Completed NCT00505778 Phase 3 Mesalamine Once-Daily;Mesalamine Twice-Daily
4 A Study of Adalimumab for the Maintenance of Clinical Remission in Japanese Subjects With Crohn's Disease Completed NCT00445432 Phase 2, Phase 3
5 Efficacy and Safety of Two Treatment Algorithms in Adults With Moderate to Severe Crohn's Disease Completed NCT01235689 Phase 3 Prednisone;Azathioprine
6 A Study Assessing the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Participants in Japan Active, not recruiting NCT03311464 Phase 3 adalimumab
7 An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum Terminated NCT02326740 Phase 3 gevokizumab;Placebo;gevokizumab open-label
8 An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum Terminated NCT02315417 Phase 3 gevokizumab;Placebo;gevokizumab open-label
9 A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma Gangrenosum Terminated NCT02318914 Phase 3 gevokizumab
10 Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma Gangrenosum Completed NCT01882504 Phase 2 gevokizumab
11 A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum Completed NCT01965613 Phase 2
12 Canakinumab for Pyoderma Gangrenosum Completed NCT01302795 Phase 2 Canakinumab
13 An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum Completed NCT03137160 Phase 2
14 Topical Tacrolimus 0.1% Ointment For Treatment Of Cutaneous Crohn's Disease Completed NCT01233570 Phase 2 Tacrolimus
15 Effect of GSK1399686 in Patients With Mild to Moderately Active Ulcerative Colitis Completed NCT01036022 Phase 2 GSK1399686
16 Single-arm Study to Assess a Potential Effect of Anti-IL-17 (Secukinumab) in the Treatment of Pyoderma Gangrenosum Recruiting NCT02733094 Phase 1, Phase 2 Secukinumab
17 Efficacy and Safety of APD334 in Patients With Pyoderma Gangrenosum Terminated NCT03072953 Phase 2 APD334
18 Safety and Efficacy Study of Humira in Treatment of Pyoderma Gangrenosum Withdrawn NCT00730717 Phase 2 Humira;Humira
19 Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum Withdrawn NCT00690846 Phase 2 adalimumab
20 Open Label Study for Adults With Pyoderma Gangrenosum and Inflammatory Bowel Disease Completed NCT00791557 Not Applicable Infliximab
21 Schnitzler Syndrome: Clinical Study, Physiopathological and Search for Genetic Factors Completed NCT00933296
22 Observational Study of the Genetic Architecture of Neutrophil-Mediated Inflammatory Skin Diseases Recruiting NCT01952275
23 Entyvio (Vedolizumab) Long Term Safety Study Recruiting NCT02674308 Vedolizumab
24 Prospective Observational Study on Ustekinumab (Stelara) Assessing Efficacy and Healthcare Resource Utilization in Crohn's Disease Active, not recruiting NCT03495973 Ustekinumab
25 Study on the Clinical Features, Comorbidities and Pathologies Associated With Pyoderma Gangrenosum Not yet recruiting NCT03636737
26 Inflammatory Bowel Disease Tracker (IBD Tracker) Not yet recruiting NCT03953794
27 Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis (RA) and Crohn's Disease (CD) Terminated NCT01577264

Search NIH Clinical Center for Pyoderma Gangrenosum

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: pyoderma gangrenosum

Sources

Genetic Tests for Pyoderma Gangrenosum

About this section
Sources

Anatomical Context for Pyoderma Gangrenosum

About this section

MalaCards organs/tissues related to Pyoderma Gangrenosum:

42
Skin, Neutrophil, Myeloid, T Cells, Bone, Thyroid, B Cells
Sources

Publications for Pyoderma Gangrenosum

About this section

Articles related to Pyoderma Gangrenosum:

(show top 50) (show all 1900)
# Title Authors Year
1
Imaging findings of sterile pyogenic arthritis, pyoderma gangrenosum and acne (PAPA) syndrome: differential diagnosis and review of the literature. ( 30225645 )
2019
2
Sequelae of breast pyoderma gangrenosum associated with ulcerative colitis: Impact on breast cancer screening. ( 31077481 )
2019
3
Pyoderma Gangrenosum After Abdominal Free Tissue Transfer for Breast Reconstruction: Case Series and Management Guidelines. ( 31095530 )
2019
4
Bullous pyoderma gangrenosum secondary to underlying multiple myeloma: treated with ciclosporin. ( 30294832 )
2019
5
A case of bullous pyoderma gangrenosum. ( 30936355 )
2019
6
Colocutaneous fistula through ulcerative colitis and cancer to the pyoderma gangrenosum: a never-ending story for a single patient. Case report. ( 30771797 )
2019
7
Pyoderma gangrenosum and primary cutaneous cryptococcosis in an ulcerative colitis patient. ( 29519678 )
2019
8
Ustekinumab in a patient with pyoderma gangrenosum and refractory Crohn's disease. ( 30795905 )
2019
9
Pyoderma gangrenosum as first manifestation of Crohn's disease. ( 30656577 )
2019
10
Pyoderma gangrenosum misdiagnosed as necrotising fasciitis or a real association between the two? ( 30897232 )
2019
11
Unilateral granuloma annulare in association with pyoderma gangrenosum and chronic lymphocytic leukemia. ( 30982302 )
2019
12
Overall and subgroup prevalence of pyoderma gangrenosum among patients with hidradenitis suppurativa: A population-based analysis in the United States. ( 30738122 )
2019
13
Pyoderma gangrenosum, acne, hidradenitis suppurativa syndrome associated with type 1 diabetes mellitus treated with adalimumab. ( 29368847 )
2019
14
Ulcerative pyoderma gangrenosum in inflammatory bowel disease. ( 31070128 )
2019
15
Successful Treatment of Pyoderma Gangrenosum With Skin Grafting in a Patient With Acute Lymphoblastic Leukemia. ( 30882508 )
2019
16
Ibrutinib and Pyoderma Gangrenosum in a Patient With B-Cell Chronic Lymphocytic Leukemia. ( 30839345 )
2019
17
Pyoderma gangrenosum: a presenting sign of myelodysplastic syndrome in undiagnosed Fanconi anemia. ( 30710899 )
2019
18
Successful treatment with ustekinumab and vacuum-assisted closure therapy in recalcitrant myelodysplastic syndrome-associated pyoderma gangrenosum: case report and literature review. ( 29851121 )
2019
19
Endovenous Treatment of Varicose Veins in Patients With Pyoderma Gangrenosum. ( 29933301 )
2019
20
Pyoderma gangrenosum reproduced by an electric current flow. ( 30010209 )
2019
21
Biologic and small-molecule medications in the management of pyoderma gangrenosum. ( 30051737 )
2019
22
Secukinumab for pyoderma gangrenosum: A case report. ( 30144933 )
2019
23
Assessing the severity of pyoderma gangrenosum: a need for validated measurement tools. ( 30171689 )
2019
24
Pyoderma gangrenosum triggered by switching from adalimumab to secukinumab. ( 30192400 )
2019
25
Epidemiology of pyoderma gangrenosum in Japanese patients by questionnaire survey. ( 30230578 )
2019
26
Efficacy and safety of etanercept for postoperative pyoderma gangrenosum after infliximab serum sickness. ( 30341800 )
2019
27
Tumor necrosis factor-α inhibitors for the treatment of pyoderma gangrenosum not associated with inflammatory bowel diseases: A multicenter retrospective study. ( 30342166 )
2019
28
Pyoderma gangrenosum misdiagnosis resulting in amputation: A review. ( 30358767 )
2019
29
Pyoderma gangrenosum and its impact on quality of life: a multicentre, prospective study. ( 30362501 )
2019
30
Tofacitinib for the Treatment of Pyoderma Gangrenosum. ( 30404036 )
2019
31
JAAD Game Changers: Clinical outcomes and response of patients applying topical therapy for pyoderma gangrenosum: A prospective cohort study. ( 30447323 )
2019
32
Pyoderma Gangrenosum After Facelift and Otoplasty Surgery: Case Presentations and Literature Review. ( 30448432 )
2019
33
Association of pyoderma gangrenosum, erythema nodosum and aseptic liver abscess without significant underlying disease. ( 30460715 )
2019
34
Hepatobiliary and Pancreatic: Pyoderma gangrenosum of the pancreas successfully treated with infliximab. ( 30467896 )
2019
35
Pyoderma gangrenosum and tumour necrosis factor alpha inhibitors: A semi-systematic review. ( 30604927 )
2019
36
Managing Ulcers Associated with Pyoderma Gangrenosum with a Urinary Bladder Matrix and Negative-Pressure Wound Therapy. ( 30653185 )
2019
37
Successful Treatment of Pyoderma Gangrenosum with Concomitant Tofacitinib and Infliximab. ( 30753456 )
2019
38
Peristomal pyoderma gangrenosum: an exceedingly rare and overdiagnosed entity? ( 30772334 )
2019
39
Management of a superinfected pyoderma gangrenosum after pacemaker implant. ( 30820397 )
2019
40
Scoring pyoderma gangrenosum. ( 30821389 )
2019
41
Pyoderma gangrenosum in a patient with lipoid proteinosis (Urbach-Wiethe disease). ( 30868669 )
2019
42
Extracutaneous involvement of pyoderma gangrenosum. ( 30923901 )
2019
43
Adalimumab plus topical tacrolimus for the treatment of pyoderma gangrenosum: Report of a case. ( 30938050 )
2019
44
Breast pyoderma gangrenosum: A rare postoperative complication of antiphospholipid antibody syndrome. ( 30945399 )
2019
45
Absence of donor-site pathergy following fractional autologous full-thickness skin grafting in pyoderma gangrenosum. ( 30947358 )
2019
46
Pyoderma gangrenosum of the vulva treated with mycophenolate mofetil and infliximab. ( 30964575 )
2019
47
Perineal pyoderma gangrenosum in pregnancy: A case report. ( 30976523 )
2019
48
Pyoderma gangrenosum succesfully treated with golimumab: Case report and review of the literature. ( 30980454 )
2019
49
Clinical factors influencing the response to intravenous immunoglobulin treatment in cases of treatment-resistant pyoderma gangrenosum. ( 30998080 )
2019
50
Pyoderma gangrenosum-like lesion secondary to methylenetetrahydrofolate reductase mutation: an unusual presentation of a rare disease. ( 31015243 )
2019
Sources

Variations for Pyoderma Gangrenosum

About this section
Sources

Expression for Pyoderma Gangrenosum

About this section
Search GEO for disease gene expression data for Pyoderma Gangrenosum.
Sources

Pathways for Pyoderma Gangrenosum

About this section

Pathways related to Pyoderma Gangrenosum according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 67
Show member pathways
 13.67 CXCL8 IFNA2 ITGB2 MEFV NLRP3 NOD2
2
Cytokine Signaling in Immune system 67
Show member pathways
 13.08 CXCL8 IFNA2 ITGB2 NOD2 TNF
3
Allograft rejection 38 1
Show member pathways
 12.62 CXCL8 IFNA2 ITGB2 TNF
4
Toll-like Receptor Signaling Pathway 1 38
Show member pathways
 12.1 CXCL8 IFNA2 MEFV NLRP3 NOD2 PSTPIP1
5
Necroptosis 38
Show member pathways
 11.95 IFNA2 NLRP3 TNF
6
Tuberculosis 38
11.81 IFNA2 ITGB2 NOD2 TNF
7
Microglia Activation During Neuroinflammation: Overview 66
Show member pathways
 11.79 ITGB2 MMP10 TNF
8
Interleukin-4 and 13 signaling 67
11.73 CXCL8 ITGB2 TNF
9
Amoebiasis 38
11.62 CXCL8 ITGB2 TNF
10
Rheumatoid arthritis 38
11.57 CXCL8 ITGB2 TNF
11
Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways 67
Show member pathways
 11.52 MEFV NLRP3 NOD2 PSTPIP1
12
Legionellosis 38
11.32 CXCL8 ITGB2 TNF
13
Immune response_Role of integrins in NK cells cytotoxicity 23
11.23 CXCL8 ITGB2
14
Malaria 38
11.23 CXCL8 ITGB2 TNF
15
Pertussis 38
11.14 CXCL8 ITGB2 NLRP3 TNF
16
Nucleotide-binding Oligomerization Domain (NOD) pathway 1
11.11 MEFV NLRP3 NOD2
17
EBV LMP1 signaling 1
10.94 CXCL8 TNF
18
Canonical NF-kappaB pathway 1
10.91 NOD2 TNF
19
Overview of nanoparticle effects 1
10.8 CXCL8 TNF
Sources

GO Terms for Pyoderma Gangrenosum

About this section

Biological processes related to Pyoderma Gangrenosum according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.88 MEFV NLRP3 NOD2 PSTPIP1
2 innate immune response GO:0045087 9.86 MEFV NLRP3 NOD2 PSTPIP1
3 cytokine-mediated signaling pathway GO:0019221 9.81 CXCL8 IFNA2 ITGB2 TNF
4 negative regulation of inflammatory response GO:0050728 9.7 MEFV MVK NLRP3
5 regulation of inflammatory response GO:0050727 9.67 NLRP3 NOD2 TNF
6 positive regulation of nitric oxide biosynthetic process GO:0045429 9.6 ITGB2 TNF
7 receptor internalization GO:0031623 9.59 CXCL8 ITGB2
8 positive regulation of interleukin-1 beta secretion GO:0050718 9.58 NLRP3 NOD2
9 positive regulation of interleukin-8 production GO:0032757 9.57 NOD2 TNF
10 cellular response to lipopolysaccharide GO:0071222 9.56 CXCL8 NLRP3 NOD2 TNF
11 microglial cell activation GO:0001774 9.55 ITGB2 TNF
12 embryonic digestive tract development GO:0048566 9.54 CXCL8 TNF
13 cellular response to peptidoglycan GO:0071224 9.48 NLRP3 NOD2
14 positive regulation of type 2 immune response GO:0002830 9.46 NLRP3 NOD2
15 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.46 ITGB2 NLRP3 NOD2 TNF
16 cellular extravasation GO:0045123 9.43 ITGB2 TNF
17 cytokine secretion involved in immune response GO:0002374 9.4 NLRP3 NOD2
18 detection of biotic stimulus GO:0009595 9.37 NLRP3 NOD2
19 defense response GO:0006952 9.35 CXCL8 IFNA2 NLRP3 NOD2 TNF
20 positive regulation of prostaglandin-E synthase activity GO:2000363 9.32 ITGB2 NOD2
21 inflammatory response GO:0006954 9.17 CXCL8 IFNA2 ITGB2 MEFV NLRP3 PSTPIP1

Molecular functions related to Pyoderma Gangrenosum according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.35 MEFV MVK NLRP3 PSTPIP1 TNF
2 cytokine activity GO:0005125 9.33 CXCL8 IFNA2 TNF
3 peptidoglycan binding GO:0042834 8.62 NLRP3 NOD2
Sources

Sources for Pyoderma Gangrenosum

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....